The Inducible CXCR3 Ligands Control Plasmacytoid Dendritic Cell Responsiveness to the Constitutive Chemokine Stromal Cell–derived Factor 1 (SDF-1)/CXCL12 by Vanbervliet, Béatrice et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/09/823/8 $8.00
Volume 198, Number 5, September 1, 2003 823–830
http://www.jem.org/cgi/doi/10.1084/jem.20020437
 
823
 
The Inducible CXCR3 Ligands Control Plasmacytoid 
 
Dendritic Cell Responsiveness to the Constitutive Chemokine 
Stromal Cell–derived Factor 1 (SDF-1)/CXCL12
 
Béatrice Vanbervliet,
 
1 
 
Nathalie Bendriss-Vermare,
 
1
 
Catherine Massacrier,
 
1 
 
Bernhard Homey,
 
2 
 
Odette de Bouteiller,
 
1
 
Francine Brière,
 
1 
 
Giorgio Trinchieri,
 
1 
 
and Christophe Caux
 
1
 
1
 
Laboratory for Immunological Research, Schering-Plough, 69571 Dardilly, France
 
2
 
Department of Dermatology, Heinrich-Heine University, D-40225 Düsseldorf, Germany
 
Abstract
 
The recruitment of selected dendritic cell (DC) subtypes conditions the class of the immune
response. Here we show that the migration of human plasmacytoid DCs (pDCs), the blood
natural interferon 
 
 
 
–producing cells, is induced upon the collective action of inducible and
constitutive chemokines. Despite expression of very high levels of CXCR3, pDCs do not
respond efficiently to CXCR3 ligands. However, they migrate in response to the constitutive
chemokine stromal cell–derived factor 1 (SDF-1)/CXCL12 and CXCR3 ligands synergize
with SDF-1/CXCL12 to induce pDC migration. This synergy reflects a sensitizing effect of
CXCR3 ligands, which, independently of a gradient and chemoattraction, decrease by 20–50-
fold the threshold of sensitivity to SDF-1/CXCL12. Thus, the ability of the constitutive che-
mokine SDF-1/CXCL12 to induce pDC recruitment might be controlled by CXCR3 ligands
released during inflammation such as in virus infection. SDF-1/CXCL12 and the CXCR3
ligands Mig/CXCL9 and ITAC/CXCL1 display adjacent expression both in secondary lym-
phoid organs and in inflamed epithelium from virus-induced pathologic lesions. Because pDCs
express both the lymph node homing molecule 
 
l
 
-selectin and the cutaneous homing molecule
cutaneous lymphocyte antigen, the cooperation between inducible CXCR3 ligands and con-
stitutive SDF-1/CXCL12 may regulate recruitment of pDCs either in lymph nodes or at pe-
ripheral sites of inflammation.
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Introduction
 
Plasmacytoid DCs (pDCs) were first characterized as plasma-
cytoid monocytes/T cells accumulating around the high
endothelial venule (HEV) of inflamed lymph nodes (for re-
view see reference 1), and later identified as a CD11c
 
  
 
DC
subset from blood and tonsils characterized by a plasmacytoid
morphology and a unique surface phenotype (CD4
 
  
 
IL-3R
 
2
 
 
 
CD45RA
 
  
 
HLA-DR
 
 
 
; 1–3). Recently, pDCs have been
demonstrated in human (4, 5) and mouse (6) to be the natural
IFN-
 
 
 
–producing cells, in response to viruses (for review
see reference 1). After exposure to viruses, pDCs induce a
potent in vitro priming and Th-1 polarization of naive T
cells, through IFN-
 
  
 
and possibly IL-12 (7, 8). Although
still unclear, the expression of lymphoid markers and the
lack of myeloid antigens suggest a lymphoid origin of
pDCs (2, 3, 9). Compared with myeloid DCs, pDCs are
activated by different signals in accordance with different
Toll-like receptor expression (10).
Under homeostasis, pDCs have not been reported in
peripheral nonimmune tissues, suggesting a different migra-
tory  capacity compared with myeloid DCs. Immature
myeloid DCs respond to many inflammatory chemokines
and are recruited at site of inflammation (11, 12). In par-
ticular, MIP-3
 
 
 
/CCL20 recruits Langerhans cells most
likely in combination with the inflammatory CCR2
ligands (13). After antigen uptake at site of infection, the
induced expression of CCR7 allows maturing myeloid
 
Address correspondence to Christophe Caux, Laboratory for Immuno-
logical Research, Schering-Plough, 27 chemin des Peupliers, BP 11,
69571 Dardilly, France. Phone: 33-4-72-17-27-00; Fax: 33-4-78-35-47-
50; email: christophe.caux@spcorp.com
 
Abbreviations used in this paper:
 
 HEV, high endothelial venule; pDC, plasma-
cytoid DC; SDF-1, stromal cell–derived factor 1.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
824
 
pDC Recruitment through Combined SDF-1/CXCL12 and CXCR3 Ligands Action
 
DCs to emigrate to the draining lymph node and elicit
immune responses (11, 12, 14).
Unlike myeloid DCs, pDCs, which express 
 
l
 
-selectin,
have been proposed to enter the lymph node from the
blood (5). However, only recently has information regard-
ing the migratory capacity of pDCs been reported (15–17).
Here we report observations arguing for a cooperation
between constitutive and inflammatory chemokines both
in pDC entry in the lymph node from blood, and in their
recruitment at peripheral inflammatory sites.
 
Materials and Methods
 
Hematopoietic Factors, Reagents, and Cell Lines.
 
2.10
 
6 
 
U/mg
hGM-CSF (Schering-Plough Research Institute), 2.10
 
7 
 
U/mg
rhTNF-
 
  
 
(Genzyme), 4.10
 
5 
 
U/mg rhSCF (R&D Systems), and
2.10
 
7 
 
U/mg rhIL-4 (Schering-Plough Research Institute) were
used at 100 ng/ml, 2.5 ng/ml, 25 ng/ml, and 50 U/ml, respec-
tively. Recombinant human chemokines were from R&D Sys-
tems (13).
 
Enrichment for CD11c
 
  
 
pDCs and CD11c
 
  
 
Myeloid DCs from Pe-
ripheral Blood and In Vitro Generation of DCs from Cord Blood
CD34
 
  
 
Hematopoietic Progenitor Cells and Monocytes.
 
Human pe-
ripheral blood was obtained anonymously from the Establissement
Francais du sang after the donor gave informed consent according
to the Declaration of Helsinki specifically indicating the possible
research use of the sample if it was not suitable for transfusion use.
Discarded human surgical material (tonsils and cord blood) was
obtained anonymously according to the institutional regulations in
compliance with French law. Circulating blood CD11c
 
  
 
pDCs
and myeloid CD11c
 
  
 
DCs were prepared from peripheral blood
as previously described (2, 13). Lineage
 
  
 
cells were removed from
mononuclear cells using antibodies and magnetic beads (anti–
mouse Ig-coated Dynabeads; Dynal). The enriched population
contained 10–30% CD11c
 
  
 
pDCs and 15–25% CD11c
 
 
 
 
 
myeloid
DCs, identified on the expression of HLA-DR (tricolor; Becton
Dickinson), CD11c (PE; Becton Dickinson), and lack of lineage
markers (FITC). For some experiments, cells were further purified
by FACS
 
® 
 
sorting based on the above triple staining.
 
Positively selected cord blood CD34
 
  
 
cells were cultured for
6 d in the presence of SCF, GM-CSF, TNF-
 
 
 
, and 5% AB
 
 
 
 
 
hu-
man serum as previously described (13).
Monocyte-derived DCs were produced by culturing mono-
cytes purified by immunomagnetic depletion for 6–7 d in the
presence of GM-CSF and IL-4 (14). T cell subsets were isolated
from peripheral blood by immunomagnetic depletion.
 
Analysis of Chemokine Receptor Expression by FACS
 
®
 
.
 
For
blood CD11c
 
  
 
pDCs, receptor expression was determined by tri-
ple staining on enriched blood DC populations and gating on
Lin
 
 
 
, CD11c
 
  
 
(FITC), and HLA-DR
 
  
 
(tricolor) using PE-cou-
pled antibodies. Similarly, for CD11c
 
  
 
myeloid DCs, receptor
expression was determined by triple staining gated on Lin
 
 
 
,
CD45RA
 
  
 
(FITC), and HLA-DR
 
  
 
(tricolor). After this protocol
the CD11c
 
  
 
pDCs were 95–98% CD45RA
 
  
 
and IL-3R
 
 
 
 
 
, and
the CD11c
 
  
 
myeloid DCs were 95–98% CD11c
 
 
 
, IL-3R
 
 
 
 
 
.
CD34-derived DCs or monocyte-derived DCs were processed
for double staining using FITC-conjugated CD1a or CD14 and
PE-conjugated mAbs.
PE anti-hCCR3 (61628.111) was from R&D Systems. PE
anti-hCXCR4 (51505.111), hCCR5 (2D7), hCCR6 (11A9),
and hCXCR3 (1C6) were from BD Biosciences. Biotinylated
anti-hCCR1 (53504.111) and hCCR2 (48607.211) from R&D
Systems, were revealed by streptavidin-PE (DakoCytomation).
Anti-hCCR7 (2H4) was a mouse IgM (BD Biosciences) revealed
by biotin-coupled goat anti–mouse IgM (Caltag). PE anti-CD83
(Immunotech) and PE anti–IL-3R
 
 
 
, FITC anti-CLA, and PE
anti-CD62L (BD Biosciences) were also used.
 
Chemotaxis Assay in Transwells.
 
Migration assays were per-
formed using transwell (6.5 mm diameter; COSTAR) with 5 
 
 
 
10
 
5 
 
cells/well as previously described (13). Enriched blood DC
populations were first preincubated for 2 h at 37
 
 
 
C and then
placed for 2 h in 5-
 
 
 
m pore size inserts. The migration was re-
vealed by triple staining gated on CD11c
 
 
 
/HLA-DR
 
 
 
/lineage
 
 
 
and CD11c
 
 
 
/ HLA-DR
 
 
 
/ lineage
 
 
 
. Monocytes, monocyte-derived
DCs, and day 6 CD34
 
  
 
hematopoietic progenitor cell–derived
DC precursors were incubated for 1–2 h in 5-
 
 
 
m pore size in-
serts and migration was revealed by CD1a/CD14 double staining.
T cells were incubated for 1 h in 3-
 
 
 
m pore size inserts and mi-
gration was revealed by CD3/CD45RA double staining.
Figure 1. pDCs do not respond to
most inflammatory chemokines. (A)
Quantitative PCR for chemokine re-
ceptors on FACS®-sorted pDCs. Results
expressed as pg/50 ng total RNA were
normalized using 18S RNA (mean of
n   3). (B) Enriched circulating blood
DC subsets were rested for 2 h at 37 C
and then studied in transwell (5- m
pore size) migration assay. Examples of
CD11c FACS® profiles of gated HLA-
DR   lineage marker   migrating cells
(representative of   10). (C) Responses
of blood CD11c  pDCs and CD11c 
myeloid DCs to various chemokines.
Each chemokine was tested over a wide
range of concentrations (1–1,000 ng/ml)
and only the optimal response is shown
(n   5).T
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Results were expressed either as migration index (ratio chemo-
kine/medium) 
 
  
 
standard deviations, or as number of migrating
cells (mean of duplicate experimental points). 
 
 
 
10% variations
were observed in these experiments.
 
Quantitative Real-Time PCR (TaqMan) Analyses of Chemokine
Receptor mRNA Expression.
 
Cells were prepared as described
above. Total RNA was extracted, reverse transcribed, and cDNA
amplified in the presence of TaqMan universal master mix (Per-
kinElmer) and gene-specific FAM-labeled TaqMan probe and
gene-specific forward and reverse primers (PerkinElmer) as previ-
ously described (13). As an internal positive control, 18S RNA-
specific JOE- or VIC-labeled TaqMan probe and primers were
added to each reaction. Gene-specific PCR products were mea-
sured with an ABI PRISMÆ 7700 Sequence Detection System
(PerkinElmer) during 40 cycles. Target gene expression was nor-
malized between different samples based on the 18S RNA values.
 
Immunohistochemistry.
 
Human tissue specimens were obtained
after the donor gave informed consent according to the Declara-
tion of Helsinki specifically indicating the possible research use of
the sample and according to the institutional review board from
the hospital (B. Homey, Research Laboratory for Dermatoimmu-
nology and Oncology Moorenstr, Düsseldorf, Germany). Frozen
6-
 
 
 
m tissue sections (human tonsils and skin) were fixed in ace-
tone (13) and nonspecific activities blocked with avidin D, biotin
solutions (Blocking kit; Vector Laboratories), and 0.3% hydrogen
peroxide (Sigma-Aldrich). After incubation with blocking serum
for 30 min, sections were immunostained with two of the follow-
ing antibodies: rabbit polyclonal anti–CD62P (BD Biosciences)
and mouse mAb anti–hMig/CXCL9 (mIgG1, 49106.11; R&D
Systems), anti-hSDF1/CXCL12 (mIgG2a, K15C; reference 18),
anti–hE-cadherin (IgG1, HECD-1; Takara), and anti-hCD105
(IgG1, 266; BD Biosciences) for 1 h at room temperature in a
humid atmosphere. Rabbit Ig was detected by biotinylated goat
anti–rabbit Ig (BA 1000; Vector Laboratories) and extravidin-per-
oxidase (Sigma-Aldrich), mouse IgG1 was revealed by sheep anti–
mouse IgG1 (Binding Site) and APAAP (DakoCytomation), and
Figure 2. Potent activity of the constitutive chemo-
kine SDF-1/CXCL12 and high CXCR4, CXCR3,
and  l-selectin expression on pDCs. CXCR4 (A),
CXCR3 (B), and l-selectin (C) cell surface expression
on DC population (representative of  3). For pDC
CXCR4, expression was also analyzed after 2 h of pre-
incubation at 37 C (A, dashed line). mRNA expression
of CXCR4 and CXCR3 was also determined by quan-
titative PCR (D) on the same populations (results ex-
pressed as pg/50 ng total RNA were normalized using
18S RNA, mean of n   3). Finally, optimal response
to CXCR4 and CXCR3 ligands is shown for each DC
population (E, mean of n   5).T
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mouse IgG2a was revealed by sheep anti–mouse IgG2a coupled to
peroxidase (Binding Site). The peroxidase and alkaline phosphatase
activities were revealed using 3-amino-9-ethylcarbazole substrate
(SK-4200; Vector Laboratories) and alkaline phosphatase substrate
III (SK-5300; Vector Laboratories), respectively. Negative controls
using isotype control primary antibodies were established.
Immunofluorescence for frozen 6-
 
 
 
m tissue sections were
fixed in acetone before the immunostaining and processed as de-
scribed above to block nonspecific activities. Sections were immu-
nostained with two of the following antibodies: rabbit polyclonal
anti–ITAC/CXCL11 (R&D Systems) and mouse mAb anti–
CD105, and anti-hSDF1/CXCL12 followed by goat anti–rabbit
IgG coupled to Alexa Fluor 488 and anti–mouse IgG coupled to
Alexa Fluor 594 (Molecular Probes) for 30 min. Negative controls
using isotype control primary antibodies were established.
 
Results and Discussion
 
pDCs Migrate in Response to the Constitutive Chemokine
Stromal Cell–derived Factor 1 (SDF-1)/CXCL12 and Express
High Levels of 
 
L
 
-
 
selectin.
 
Freshly isolated human pDCs ex-
pressed cell surface CCR2 and CCR5 at comparable levels
to CD11c
 
  
 
blood DCs (not depicted), in agreement with a
recent study (15). However, unlike blood CD11c
 
  
 
DCs
(Fig. 1) and other DC subsets (12, 13, 15), pDCs only
marginally responded to CCR2 (MCPs) and CCR5
(RANTES/CCL5) ligands (Fig. 1). pDCs neither signifi-
cantly expressed CCR1, CCR3, CCR4, CCR6, CCR,
CXCR1, CXCR2, CXCR5 as detected by cytofluorome-
try (not depicted), and/or RT-PCR (Fig. 1 A), nor did
they respond to their ligands (Fig. 1 C). In contrast, pDCs
highly expressed CXCR4 and CXCR3 both at mRNA
and surface protein levels (Figs.1 A and 2, A, B, and D).
However, although pDCs migrated efficiently in response
to the CXCR4 ligand SDF-1/CXCL12 with an IC50 of
 
 
 
100 ng/ml (Figs. 1, B and C, 2 E, and 3 A), they only
marginally respond to CXCR3 ligands (Figs. 1 C and 2 E).
Compared with other DC subsets, SDF-1/CXCL12 was
preferentially active on pDCs (Fig. 2 E), likely as a conse-
quence of high CXCR4 mRNA (Fig. 2 D) and protein
(Fig. 2 A), further increased at cell surface upon 2 h culture
(Figs. 2 A and 4 C). SDF-1/CXCL12 displays a constitu-
tive but restricted expression pattern in situ, with selective
expression on dermal endothelial cells (18) and in lymph
node HEVs (17). pDCs are primarily localized within the T
Figure 3. CXCR3 ligands selectively induce pDCs to
respond to low SDF-1/CXCL12 concentration. (A) Dose
response to IP-10/CXCL10 of pDCs in the presence or
absence of a low dose of SDF-1/CXCL12 (10 ng/ml). (B)
Dose response to SDF-1/CXCL12 of pDCs in the presence
or absence of 1  g/ml IP-10/CXCL10. (C) Response of
pDCs to all CXCR3 ligands (1  g/ml), tested individu-
ally, in the presence or absence of a low dose of SDF-1/
CXCL12 (10 ng/ml). (D) Dose response to SDF-1/
CXCL12 of FACS®-sorted CD11c  pDCs and CD11c 
myeloid DCs in the presence or absence of 1  g/ml IP-10/
CXCL10. (E) Effects of 1  g/ml IP-10/CXCL10 on the
dose response to SDF-1/CXCL12 of various DC and T
cell populations. Results are expressed as folds of IP-10–
induced migration over that of SDF-1/CXCL12 alone
(ratio migration index in SDF-1/CXCL12    IP-10/
CXCL10/migration index in SDF-1/CXCL12 alone).
Results from n   3.T
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cell area of inflamed lymphoid organs, around the HEV (1).
In agreement with a previous study (5), pDCs expressed
much higher levels of 
 
l
 
-selectin than other DC subsets
(Fig. 2 C), at a density comparable to that of naive T cells.
The constitutive expression of SDF-1/CXCL12 and of
 
l
 
-selectin ligands on HEVs might be responsible for the
trafficking of pDCs from the blood to the lymph nodes in
homeostatic conditions. This hypothesis is supported by the
observed pDC deficiency in lymph nodes from 
 
l
 
-selectin–
deficient mice (19). Thus, pDC migration could be reminis-
cent of that of naive T cells from the blood to the lymph
nodes through 
 
l
 
-selectin ligands and the CCR7 ligand
6Ckine/CCL21 expressed by HEV (11). However, CCR7
ligands are unlikely to be involved for resting pDC recruit-
ment as they lack CCR7 expression. The model proposed
here would imply that unlike myeloid DCs that capture
pathogens in peripheral tissues and consequently migrate in
lymph nodes, pDCs are constitutively recruited in lymph
nodes, where they might be exposed to infectious agents.
The Inducible CXCR3 Ligands Regulate pDC Respon-
siveness to the Constitutive Chemokine SDF-1/CXCL12.
Among chemokine receptors in pDCs, CXCR3 was ex-
pressed at the highest level (Fig. 1 A) and was absent on all
other DC populations as detected by immunofluorescence at
cell surface, or by quantitative RT-PCR (Fig. 2, B and D).
However, only high concentrations (1–5  g/ml) of the
CXCR3 ligands IP-10/CXCL10, Mig/CXCL9, and I-TAC/
CXCL11 induced significant but modest migration of pDCs
(Figs. 1 C and 3, A and C). In the presence of a suboptimal
dose of SDF-1/CXCL12 (10 ng/ml), IP-10/CXCL10 at a
lower concentration (100–1,000 ng/ml) induced brisk mi-
gration of pDCs (Fig. 3 A). In combination with SDF-1/
CXCL12, all CXCR3 ligands dramatically decreased the
threshold of SDF-1/CXCL12 sensitivity by 20–50-fold (Fig.
3, B and C). These observations were confirmed on purified
FACS®-sorted pDCs (Fig. 3 D) and extend a very recent
study (17).
With FACS®-sorted CD11c  circulating blood “my-
eloid DCs,” no synergistic activity was observed (Fig. 3 D).
Also, neither the other DC populations tested (monocyte-
derived DCs and CD34-derived DC subsets) nor naive T
cells displayed synergistic response (Fig. 3 E), in agreement
with the lack of CXCR3 expression on these cells.
However, a synergistic activity was observed in CD3 
CD45RA  memory T cells that coexpress CXCR4 and
CXCR3 (Fig. 3 E).
To investigate the mechanism of the synergy, SDF-1/
CXCL12 and CXCR3 ligands were opposed in upper and
lower wells (Fig. 4 A). Synergy was observed when SDF-
1/CXCL12 and IP-10/CXCL10 were added together in
Figure 4. CXCR3 ligands prime pDCs to respond to
low SDF-1/CXCL12 concentrations. (A) Experiments
were performed as a typical transwell migration assay with
20 ng/ml SDF-1/CXCL12 and 1  g/ml IP-10/CXCL10,
except that the upper well can also contain a chemokine.
When both the upper and lower wells contain the same
chemokine, the migration was identical or lower to that in
medium alone (not depicted). (B) Preincubation experi-
ments wherein the cells were first incubated in the presence of
20 ng/ml SDF-1/CXCL12 and 1  g/ml IP-10/CXCL10
for 1 h before performing the migration assay to both re-
ceptor ligands in transwell. When the same chemokine was
used in the preincubation and in the migration assay, the
migration was identical or lower to that in medium alone
(not depicted). Results are from n   3. (C) pDCs were in-
cubated in presence of 20 ng/ml SDF-1/CXCL12, 1  g/ml
IP-10/CXCL10, or medium for 1.5 h at 37 C before per-
forming the staining for CXCR4 (representative of n   3).
(D) CLA expression was performed on the different DC
populations and monocytes by triple or double staining
(representative of n   4).T
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Figure 5. Mig/CXCL9 and ITAC/
CXCL11 expression in blood vessels of T
cell area of tonsils and of inflamed epithe-
lium, is adjacent to that of SDF-1/CXCL12
by epithelial cells and in close contact with
IL-3R–expressing pDCs. (A) Immunohis-
tochemistry in 6- m tonsil serial sections
fixed in acetone showing detection of Mig/
CXCL9 by endothelial cells in the T cell
area (b and c) and in the crypt (g) contact-
ing epithelial cells expressing SDF-1/
CXCL12 (e and f) and IL-3R  pDCs (h and
i) within the network of SDF-1/CXCL12 
epithelial cells. Isotype match controls were
performed (a, the T cell area; d, the epithe-
lial crypt). a–c,  200; d–f,  100; g–i,
 400. (B) Immunohistochemistry in 6- m
serial sections fixed in acetone from normal
skin, psoriatic lesion, and biopsies of verrucae
vulgaris and molluscum contagiosum showing
Mig/CXCL9 (e–h) expression in lesions by
cells contacting CD105  blood vessels (i–l)
and epithelial sites of constitutive SDF-1/
CXCL12 expression (sweat gland; e–l), in-
filtrated by IL-3R–expressing pDCs (m–p).
The specificity of the immunostainings was
demonstrated using isotype match controls
(a–d).   400. (C) Immunofluorescence in
6- m serial sections fixed in acetone show-
ing adjacent ITAC/CXCL11 expression to
that of SDF-1/CXCL12 by epithelial cells
in tight contact with blood vessels in epi-
thelial crypt of tonsils (d and g) and in sweat
gland of both normal (e and h) and psoriatic
(f and i) skin. The specificity of the immu-
nostainings was demonstrated using isotype
match controls (a–c).  400. All of these
observations were reproduced on more
than three independent specimens.
the lower well (4.5-fold increase), as well as when IP-10/
CXCL10 was in the upper well together with pDCs and
SDF-1/CXCL12 in the lower well (threefold increase).
In the reverse condition, no migration was observed.
Similarly when pDCs were preincubated with IP-10/
CXCL10, a three- to fivefold increased response to SDF-
1/CXCL12 was observed, whereas SDF-1/CXCL12 did
not prime them for responsiveness to IP-10/CXCL10
(Fig. 4 B). Identical results were obtained with the other
CXCR3 ligands (not depicted). When similar experiments
were performed with other chemokines (CCR2 or CCR5
ligands combined with CXCR3 ligands), no synergy was
observed (not depicted).These results show that CXCR3
ligand activity was independent of a gradient, thus not
linked to chemoattraction, and was likely due to a sensiti-
zation of the cells that allowed them to respond to lower
SDF-1/CXCL12 concentrations. CXCR3 ligand activity
was CXCR3 mediated as CXCR3 down-regulation was
observed. The increase in SDF-1/CXCL12 responsiveness
was not due to CXCR4 up-regulation as preincubation in
IP-10/CXCL10 had no detectable effects on CXCR4 ex-
pression (Fig. 4 C). The CXCR3 ligands are inflammatory
chemokines induced by IFN and other activators. Induc-
tion of IP-10/CXCL10 and Mig/CXCL9 primarily medi-
ated by IFN- /  has been shown in several mouse and
primate models within hours after virus challenge (20–23).T
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These observations, together with the recently published
study on mouse pDCs (17), suggest that during viral infec-
tion or other inflammatory responses the induction of
CXCR3 ligands might drive the recruitment of pDCs,
and a subset of memory T cells, at sites of constitutive
SDF-1/CXCL12 production. These observations repre-
sent, to our knowledge, the first descriptions that the ac-
tivity of constitutive chemokines can be controlled by in-
flammatory chemokines.
The CXCR3 Ligands Mig/CXCL9, ITAC/CXCL11,
and SDF-1/CXCL12 Display Adjacent Expression Both in
Lymphoid Organs and in Inflamed Epithelial Surfaces. The
distribution of SDF-1/CXCL12 and CXCR3 ligands in
inflamed tissues was studied by immunohistology on tonsil,
psoriatic lesions, and biopsies of verrucae vulgaris and mollus-
cum contagiosum (Fig. 5). In the T cell area of tonsils, Mig/
CXCL9 was expressed by endothelial cells in few blood
vessels (Fig. 5 A, b and c). Although SDF-1/CXCL12 has
been recently reported to be expressed in lymph nodes by
endothelial cells (17), it was not detectable in the T cell
area in tonsils (not depicted). In contrast, SDF-1/CXCL12
was strongly expressed by the network of epithelial cells in
the crypt but not by CD105  endothelial cells (Fig. 5 A, e
and f). Mig/CXCL9 expression was observed in the same
area, possibly in blood vessels contacting the basal layer of
the crypt expressing SDF-1/CXCL12 (Fig. 5 A, g). By
immunofluorescent staining, ITAC/CXCL11 expression
was detected on epithelial cells contacting in most in-
stances those expressing SDF-1/CXCL12 and blood ves-
sels (Fig. 5 C, d and g). Furthermore, pDCs detected by
IL-3R expression were observed within the network of
crypt epithelial cells expressing SDF-1/CXCL12 (Fig. 5 A,
h and i). On normal skin and nonlesional skin (not de-
picted), high SDF-1/CXCL12 expression was detected by
epithelial cells (E-cadherin ; not depicted) of sweat glands
(Fig. 5 B, e, i, and m) but not by basal keratinocytes (not
depicted) as previously reported (18), whereas Mig/
CXCL9 expression was not detected (Fig. 5 B, e). In con-
trast, in psoriatic skin, Mig/CXCL9 was highly expressed,
always in close association with blood vessels and epithelial
cells of sweat glands expressing SDF-1/CXCL12 (Fig. 5 B,
f and j). Similarly, ITAC/CXCL11 was systemically ex-
pressed in cells in tight association with blood vessels or
endothelial cells themselves, surrounding SDF-1/CXCL12
expressing epithelial sweat glands, both in normal and pso-
riatic skin (Fig. 5 C, e, f, h, and i). Finally, in most in-
stances in biopsies of viral-induced skin inflammation,
Mig/CXCL9 (Fig. 5 B, g, h, k, and l) and ITAC (not de-
picted) expression contacted epithelial structures expressing
SDF-1/CXCL12 and blood vessels. Furthermore, these
structures were surrounded by IL-3R–expressing cells. Al-
though some of these IL-3R  cells might represent endo-
thelial cells, the isolated IL-3R cells were pDCs (Fig. 5 B,
n–p), as confirmed by stainings with the pDC markers
BDCA4 and BDCA2 (not depicted).
From these observations, it can be hypothesized that
during viral dissemination, the cooperation between CXCR3
ligands and SDF-1/CXCL12 may control the recruitment
of pDCs from blood both in the draining lymph node as
well as into the site of infection itself. This is consistent
with the expression of the cutaneous homing molecule
CLA by pDCs like other circulating DCs and monocytes
(Fig. 4 D). This is in agreement with the presence of pDCs
documented in the nasal mucosa (24) and in skin from pa-
tients suffering from Lupus erythematosus (25), in which
SDF-1/CXCL12 production was previously reported (18).
Finally, the first clinical manifestation of a particular leuke-
mia representing tumorogenic pDCs (26) is the occurrence
of cutaneous lesions likely due to the infiltration of leuke-
mic pDCs (27). This represents another argument to sug-
gest that normal pDCs might also have the capacity to
reach nonlymphoid tissues.T
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